LAS VEGAS--(BUSINESS WIRE)--May 18, 2006--CardioVascular BioTherapeutics, Inc. (OTCBB:CVBT - News) has achieved a safety milestone in its Phase I clinical trial carried out in patients with severe coronary artery disease. This Phase I clinical trial included three escalating dose groups and no significant unexpected adverse events were attributable to CVBT’s drug candidate in the patients who received treatment. Enrollment and treatment of all patients as specified in the FDA-authorized clinical protocol has been completed.
